Novotech White Papers

  1. 2025 Global Report For In-Vivo CAR Cell Therapy 8/14/2025

    Explore global trends shaping in-vivo CAR therapies—delivery innovations, clinical trial momentum, and regulatory strategies across oncology and autoimmune diseases.

  2. LBPs: Unique Quality, Manufacturing, And Nonclinical Considerations 8/14/2025

    Live biotherapeutic products (LBPs) are emerging as a dynamic area of drug development, and their development demands tailored strategies that address both manufacturing and nonclinical complexities.

  3. In-Vivo CAR Therapies — Global Research And Development Landscape 7/15/2025

    Delve into the evolving in-vivo CAR therapy landscape, examining key technological innovations, major industry players, recent clinical progress, and regulatory developments.

  4. Live Biotherapeutic Products: Unique Quality, Manufacturing, And Nonclinical Considerations For Clinical Trial Entry 7/8/2025

    Live biotherapeutic products (LBPs) represent an emerging frontier in therapeutic development, harnessing living microorganisms to prevent, treat, or cure disease.

  5. IPF - Global Clinical Trial Landscape 5/19/2025

    This report provides a comprehensive overview of Idiopathic Pulmonary Fibrosis (IPF), a progressive and fatal interstitial lung disease.

  6. Infectious Diseases - Global Clinical Trial Landscape (2025) 5/14/2025

    The global infectious disease clinical trial landscape has rapidly expanded between 2020 and 2024, driven by the urgency of emerging threats, technological innovation, and evolving regulatory frameworks.

  7. Obesity - Global Clinical Trial Landscape (2025) 5/14/2025

    This report analyzes the current state of global and Asia-Pacific obesity trials, highlighting regional trends, sponsor activity, and preferred endpoints.

  8. Small Cell Lung Cancer- Global Clinical Trial Landscape (2025) 5/9/2025

    Historically dominated by chemotherapy and radiation, the treatment paradigm for small cell lung cancer (SCLC) is evolving in response to limited survival benefits and high relapse rates.

  9. Optimizing siRNA Therapeutics: Addressing Manufacturing Complexities 3/21/2025

    Discover key strategies to optimize siRNA therapeutics by addressing critical nonclinical and manufacturing challenges for a smoother path to commercialization.

  10. Hepatitis B - Global Clinical Trial Landscape 3/6/2025

    As Hepatitis B virus (HBV) clinical trials advance, refining therapeutic endpoints and integrating novel treatment strategies are essential to transforming Hepatitis B management.